March 11, 2013
/PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Hong Kong Adventist Oncology Center
the first center locally to offer both the CyberKnife® Robotic Radiosurgery and TomoTherapy® Systems, hosted its official opening ceremony last week. Hong Kong Adventist Oncology Center is a newly built cancer center that was designed to accommodate both systems. Their TomoTherapy System was installed late last year and their CyberKnife System was installed in
"We are pleased to offer the most flexible, precise solutions for radiation treatment planning and delivery that enable us to deliver personalized treatments to a wide range of patients," said Dr.
, clinical director of Hong Kong Adventist Oncology Center. "The CyberKnife and TomoTherapy Systems allow our clinicians to create specialized treatments ranging from high-precision radiosurgery for early-stage and localized disease to image-guided, intensity-modulated radiation therapy (IG-IMRT) for more advanced disease throughout the body."
"Our two leading-edge treatment solutions – the CyberKnife and the TomoTherapy Systems – satisfy all the external beam radiation delivery needs of an oncology department and give clinicians flexible, individualized treatment options to use in their pursuit of optimal treatment outcomes." said Lionel Hadjadjeba, general manager EIMEA and senior vice president of International Business at Accuray. "The adoption of Accuray's versatile systems are constantly proven to provide comprehensive treatment solutions that serve the full spectrum of radiation oncology patients."
For more information of Hong Kong Adventist Oncology Center, please visit
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on
September 10, 2012
, as updated in our Form 10-Qs filed on
November 8, 2012
February 6, 2013
, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated